Clinical Drug Investigation

, Volume 30, Issue 2, pp 89–100 | Cite as

Impact of Adherence to Interferons in the Treatment of Multiple Sclerosis

A Non-Experimental, Retrospective, Cohort Study
  • Stephanie C. Steinberg
  • Richard J. Faris
  • Cyril F. Chang
  • Andrew Chan
  • Mark A. Tankersley
Original Research Article

Abstract

Background: Relapsing-remitting multiple sclerosis (RRMS) is a chronic disease affecting about 400 000 people in the US characterized by increasing patient disability and burden on society. While there is no cure for multiple sclerosis (MS), pharmaceutical treatments exist that can limit the number of relapses a patient experiences, and slow disease progression. One such class of agents used to treat RRMS are the interferons: interferon-β-1a (Rebif® and Avonex®) and interferon-β-1b (Betaseron® and Extavia®). Patients must take these injectable medications regularly to achieve the optimal outcomes. However, patient issues and potential adverse effects of the medication may prevent the patient from taking the medication as directed and lower adherence. To date, limited evidence exists regarding the effect of patient adherence to interferon-β therapies on clinical and economic outcomes.

Objective: The purpose of this study was to explore the impact of patient adherence to interferon-β therapy on MS relapse rates and healthcare resource utilization.

Methods: Using a non-experimental, retrospective cohort design, a sample population (n= 1606) was drawn from patients identified in a database that includes both pharmacy and medical claims data. The study population was separated into two groups based on a measure of medication possession ratio (MPR)-adherent and non-adherent patients, and adherence was defined as MPR ≥85% in a given year during the study period (2006–8). Key outcome variables included MS relapses and healthcare resource utilization. Data were analysed using parametric and non-parametric statistics, and regression modeling.

Results: During the study period, the average MPR for all patients on interferon-β therapy varied from 72% to 76%. Only 27–41% of patients in each year were considered adherent (i.e. MPR ≥85%) and only 4% of patients had an MPR of ≥85% throughout the 3-year study period (2006–8). Patients who were adherent tended to have a lower risk of relapses over 3 years than non-adherent patients. A significantly lower risk of relapses was found in 2006 (risk ratio [RR] 0.89; 95% CI 0.81, 0.97). Furthermore, an increasingly larger effect emerged between adherence and relapses when comparing adherent patients (MPR ≥85%) with subgroups of non-adherent patients (<80%, <75%, <70%, <65% and <60%). The impact of adherence on emergency room (ER) visits also tended to suggest a lower risk during 2006, 2007 and 2006–8. During 2008, the risk for an ER visit was significantly lower for patients adherent in 2007 (RR 0.78; 95% CI 0.61, 0.99). Inpatient admissions followed the ER trends, as patients considered adherent in 2006 and 2007 tended to have a lower risk over 3 years. This result was significant for patients adherent in 2007 (RR 0.79; 95% CI 0.65, 0.98).

Conclusion: The findings of low patient adherence and the impact of adherence on relapses and healthcare resource utilization strongly suggest opportunities to reduce healthcare resource utilization and healthcare costs among RRMS patients taking interferon-β therapy. Efforts should be undertaken to understand and improve medication-taking behaviour in this population so as to minimize the negative impacts of RRMS on patients while reducing unnecessary direct and indirect costs to treat disease exacerbations.

Notes

Acknowledgements

Funding for this study was provided by Merck-Serono. Richard Faris, Stephanie Steinberg and Mark Tankersley are employed by Accredo Health Group, Inc. Dr Cyril Chang is employed by the University of Memphis, and was retained as a consultant for design, analysis and review of this project. Dr Andrew Chan is the Deputy Head of the Department of Neurology at St Josef-Hospital, Ruhr-University Bochum. Dr Chan has served on advisory boards and has received research support and speakers honoraria from Bayer Schering, Biogen Idec, Merck-Serono, Novartis, Sanofi-Aventis and Teva.

References

  1. 1.
    Rudick RA, Goodkin DE, editors. Multiple sclerosis therapeutics. London: Martin Dunitz Ltd, 2000Google Scholar
  2. 2.
    National multiple sclerosis society [online]. Available from URL: http://www.nationalmssociety.org/about-multiple-sclerosis [Accessed 2009 Oct 12]
  3. 3.
    Goodin DS, Frohman EM, Garmany GP, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002 Jan; 58(2): 169–78PubMedCrossRefGoogle Scholar
  4. 4.
    Manfredonia F, Pasquali L, Dardano A, et al. Review of the clinical evidence for interferon B 1a (Rebif) in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat 2008 Apr 4 (2): 321-36Google Scholar
  5. 5.
    Lublin F, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 2003; 61: 1528–32PubMedCrossRefGoogle Scholar
  6. 6.
    Johnson KL, Kuehn CM, Yorkston KM, et al. Patient perspectives on disease-modifying therapy in multiple sclerosis. Int J MS Care 2006; 8: 11–8CrossRefGoogle Scholar
  7. 7.
    Treadway K, Cutter G, Salter A, et al. Factors that influence adherence with disease-modifying therapy in MS. J Neurol 2009 April; 256(4): 568–76CrossRefGoogle Scholar
  8. 8.
    Flachenecker P, Rieckmann P. Early intervention in multiple sclerosis: better outcomes for patient and society? Drugs 2003; 63: 525–33CrossRefGoogle Scholar
  9. 9.
    Comi G. Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta. Clin Ther 2009 Jun; 31(6): 1142–57PubMedCrossRefGoogle Scholar
  10. 10.
    Jewell S. Issues in adherence: initiating and maintaining patients on immunotherapy. Multiple Sclerosis Pro 2001 [online]. Available from URL: http://www.multiplesclerosispro.com/admin/templates/Template_Nurse_Issues.aspx?artic. [Accessed 2009 Oct 18]
  11. 11.
    National Institute of Neurological Disorders and Stroke: 2009 [online]. Available from URL: http://www.ninds.nih.gov/disorders/multiplesclerosis/detail_multiple_sclerosis.htm [Accessed 2009 Nov 10]
  12. 12.
    Kolbelt G, Lindgren P, Smala A, et al. Costs and quality of life in multiple sclerosis: an observational study in Germany. HEPAC 2001; 2: 60–8CrossRefGoogle Scholar
  13. 13.
    Pope GC, Urato CJ, Kulas ED, et al. Prevalence, expenditures, utilization, and payment for persons with MS in insured populations. Neurology 2002; 58: 37–43PubMedCrossRefGoogle Scholar
  14. 14.
    Grima DT, Torrance GW, Francis G, et al. Cost and health-related quality of life consequences of multiple sclerosis. Mult Scler 2000; 6(2): 91–8Google Scholar
  15. 15.
    Miltenburger C, Kobelt G. Quality of life and cost of multiple sclerosis. Clin Neurol Neurosurg 2002; 104(3): 272–5PubMedCrossRefGoogle Scholar
  16. 16.
    O’Brien JA, Ward AJ, Patrick AR, et al. Cost of managing an episode of relapse in multiple sclerosis in the United States. BMC Health Serv Res 2003 Sept; 3: 17PubMedCrossRefGoogle Scholar
  17. 17.
    Portaccio E, Zipoli V, Siracusa G, et al. Long-term adherence to interferon ß therapy in relapsing-remitting multiple sclerosis. Eur Neurol 2008; 59(3-4): 131–5PubMedCrossRefGoogle Scholar
  18. 18.
    Recognizing nonadherence in patients with MS: defining adherence [online]. Available from URL: http://www.medscape.com/view article/579661 3 [Accessed 2009 Aug 2]
  19. 19.
    Vercellino M, Romagnolo A, Mattioda S, et al. Multiple sclerosis relapses: a multivariable analysis of residual disability determinants. Acta Neurol Scand 2009 Feb; 119(2): 126–30PubMedCrossRefGoogle Scholar
  20. 20.
    Klauer T, Zette UK. Compliance, adherence, and the treatment of multiple sclerosis. J Neurol 2008 Dec; 255Suppl. 6: 87–92PubMedCrossRefGoogle Scholar
  21. 21.
    Tremlett H, Van der Mei I, Pittas F, et al. Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses. Pharmacoepidemiol Drug Saf 2008 Apr; 17(6): 565–76PubMedCrossRefGoogle Scholar
  22. 22.
    Zycynski TM, Coyne KS. Hypertension and current issues in compliance and patient outcomes. Curr Hypertens Rep 2000; 2(6): 510–4CrossRefGoogle Scholar
  23. 23.
    Cramer JA, Benedict A, Muszbeck N, et al. The significance of compliance and persistence in the treatment of diabetes, hypertension and dysplipidaemia: a review. Int J Clin Practice 2008 Jan; 62(1): 76–87CrossRefGoogle Scholar
  24. 24.
    Revel M. Interferon-B in the treatment of relapsing-remitting multiple sclerosis. Pharmacol Therap 2003 Oct; 100(1): 49–62CrossRefGoogle Scholar
  25. 25.
    Portaccio E, Amato MP. Improving compliance with interferon-beta therapy in patients with multiple sclerosis. CNS Drugs 2009; 23(6): 453–62PubMedCrossRefGoogle Scholar
  26. 26.
    MacLean HJ, Freedman MS. Immunologic therapy for relapsing-remitting multiple sclerosis. Curr Neurol Neurosci Rep 2001 May; 1(3): 277–85PubMedCrossRefGoogle Scholar
  27. 27.
    McCormack PL, Scott LJ. Interferon-beta-1b: a review of its use in relapsing-remitting and secondary progressive multiple sclerosis. CNS Drugs 2004; 18(8): 521–46PubMedCrossRefGoogle Scholar
  28. 28.
    Grymonpre R, Cheang M, Fraser M, et al. Validity of a prescription claims database to estimate medication adherence in older persons. Med Care 2006 May; 44(5): 471–7PubMedCrossRefGoogle Scholar
  29. 29.
    Fairman K, Motheral B. Evaluating medication adherence: which measure is right for your program? J Manag Care Pharm 2000; 6: 499–506Google Scholar
  30. 30.
    Friedman DS, Quigley HA, Gelb L, et al. Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistence Study (GAPS). Invest Ophthalmol Vis Sci 2007; 48: 5052–7PubMedCrossRefGoogle Scholar
  31. 31.
    Johnson RE, Volmer WM. Comparing sources of drug data about the elderly. J Am Geriatr Soc 1991; 39: 1079–84PubMedGoogle Scholar
  32. 32.
    Kirking DM, Ammann MA, Harrington CA. Comparison of medical records and prescription claims files in documenting prescription medication therapy. J Pharmaco-epidemiol 1996; 5(1): 3–15Google Scholar
  33. 33.
    Lau HS, De Boer A, Beuning KS, et al. Validation of pharmacy records in drug exposure assessment. J Clin Epidemiol 1997; 50(5): 619–25PubMedCrossRefGoogle Scholar
  34. 34.
    Tamblyn R, Lavoie G, Petrella L, et al. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995 Aug; 48(8): 999–1009PubMedCrossRefGoogle Scholar
  35. 35.
    Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care 2005 Jul; 7(11): 449–57Google Scholar
  36. 36.
    Osterberg L, Blaschke T. Adherence to medication. N Eng J Med 2005 Aug; 132: 487–97CrossRefGoogle Scholar
  37. 37.
    Steiner JF, Earnest MA. The language of medication taking. Ann Intern Med 2000; 132: 926–30PubMedGoogle Scholar
  38. 38.
    Peterson AM, Nau DP, Cramer JA, et al. A checklist for medication compliance and persistence using retrospective databases. Value Health 2007 Jan–Feb; 10(1): 3–12PubMedCrossRefGoogle Scholar
  39. 39.
    Ruggieri RM, Settipiani N, Viviano L, et al. Long-term interferon-ß treatment for multiple sclerosis. Neurol Sci 2003 Dec; 24(5): 361–4PubMedCrossRefGoogle Scholar
  40. 40.
    Schumacker GA, Beebe G, Kebler RF, et al. Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann NY Acad Sci 1965; 122: 552–68PubMedCrossRefGoogle Scholar
  41. 41.
    Goldberg P, Fleming MC, Picard EH. Multiple sclerosis: decreased relapse rate through dietary supplementation with calcium, magnesium, and vitamin D. Med Hypotheses 1986 Oct; 21: 193–200PubMedCrossRefGoogle Scholar
  42. 42.
    Buljevac D, Hop WC, Reedeker AC, et al. Self reported stressful life events and exacerbations in multiple sclerosis: prospective study. BMJ 2003; 327: 646–9PubMedCrossRefGoogle Scholar
  43. 43.
    Putnam KG, Buist DS, Fishman P, et al. Chronic disease score as a predictor of hospitalization. Epidemiology 2002 May; 13(3): 340–6PubMedCrossRefGoogle Scholar
  44. 44.
    Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 2004 Oct; 39(3): 285–94CrossRefGoogle Scholar
  45. 45.
    Tang J, Faris RJ. Exploring the impact of dispensing channel on medication adherence among multiple sclerosis patients. ISPOR 14th Annual International Meeting; 2009 May 16–20; Orlando (FL)Google Scholar
  46. 46.
    Garcia DO, Knobel H, Carmona A, et al. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr 2002; 30(1): 105–10Google Scholar
  47. 47.
    Brigido LF, Rodrigues R, Casseb J, et al. Impact of adherence to antiretroviral therapy in HIV-1-infected patients at a university public service in Brazil. AIDS Patient Care STDS 2001 Nov; 15(11): 587–93PubMedCrossRefGoogle Scholar
  48. 48.
    DeMasi RA, Graham NM, Tolson JM, et al. Correlation between self-reported adherence to highly active antiretroviral therapy (HAART) and virologic outcome. Adv Ther 2001; 18(4): 163–73PubMedCrossRefGoogle Scholar
  49. 49.
    Gwadry-Sridhar F, Manias E, Zhang Y, et al. A framework for planning and critiquing medication compliance and persistence research using prospective study designs. Clin Ther 2009 Feb; 31(2): 421–35PubMedCrossRefGoogle Scholar
  50. 50.
    Daugherty KK, Butler JS, Mattingly M, et al. Factors leading patients to discontinue multiple sclerosis therapies. J Am Pharm Assoc 2005 May–Jun; 45(3): 371–5CrossRefGoogle Scholar
  51. 51.
    Munschauer FE, Tyree J. Persistency in patient with multiple sclerosis. Paper presented at the Annual Meeting of the Consortium of MS Centers (CMSC) 2004 Jun 4; Toronto (ON)Google Scholar
  52. 52.
    Tremlett HL, Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology 2003; 61: 551–4PubMedCrossRefGoogle Scholar
  53. 53.
    Kreuger KP, Berger BA, Felkey B. Medication adherence and persistence: a comprehensive review. Adv Ther 2005 Jul–Aug; 22(4): 313–56CrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  • Stephanie C. Steinberg
    • 1
  • Richard J. Faris
    • 2
  • Cyril F. Chang
    • 3
  • Andrew Chan
    • 4
  • Mark A. Tankersley
    • 2
  1. 1.Accredo Health Group, Inc.The University of MemphisMemphisUSA
  2. 2.Health Outcomes, Accredo Health Group, Inc.MemphisUSA
  3. 3.Methodist-Le Bonheur Center for Healthcare EconomicsThe University of MemphisMemphisUSA
  4. 4.Department of Neurology, St Josef-HospitalRuhr-University BochumBochumGermany

Personalised recommendations